Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pregnancy-Associated Aplastic Anemia
Acta Haematologica · 13.03.2026 · 1-14
DOI: 10.1159/000551296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 13.03.2026. Verfasst von Xinxin Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Introduction
The prognosis and management of pregnancy-associated aplastic anemia (PAA) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain uncertain. This retrospective study was conducted to describe our clinical experience and to explore the efficacy and safety of allo-HSCT in patients with PAA.
Methods
A retrospective observational study was evaluated the safety and feasibility of allo-HSCT in 18 patients with PAA who were treated between January 2013 and November 2023.
Results
Median neutrophil engraftment occurred at 11.5 days (range: 6–15), and platelet engraftment occurred at 11.5 days (range: 7–28). The cumulative incidence (CuI) of both neutrophil and platelet engraftment was 100%. The CuI rates were 22.96% (95% CI, 13.68–27.32) for grade II acute graft-versus-host disease (aGVHD) and 12.61% (95% CI, 9.32–29.28) for chronic GVHD (cGVHD). No cases of grade III–IV aGVHD, extensive cGVHD, or relapse were observed. The CuI of transplantation-related mortality was 19.87% (95% CI, 13.15–30.73). Among the 15 surviving patients, the median follow-up was 47.0 months (range: 7.6–122.2 months). The overall survival and relapse/rejection-free rates were both 80.14% (95% CI, 69.27–86.86).
Conclusion
These findings suggest that allo-HSCT is a viable and effective treatment option for PAA. The donor types included 8 matched sibling donors, 1 matched unrelated donor, 3 mismatched unrelated donors, and 6 haploidentical donors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
- Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.
- Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China, eywangshq@scut.edu.cn.
- Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China, eywangshq@scut.edu.cn.
- Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China, eyzhangyuping@scut.edu.cn.
- Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China, eyzhangyuping@scut.edu.cn.
Zitieren
APA
Li, X., Wu, L., Li, Y., Mo, W., Chen, X., Zhou, M., Zhou, R., Xu, S., Pan, S., Wang, C., Wang, S., & Zhang, Y. (2026). Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pregnancy-Associated Aplastic Anemia. Acta Haematologica, 1-14. https://doi.org/10.1159/000551296
Vancouver
Li X, Wu L, Li Y, Mo W, Chen X, Zhou M, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pregnancy-Associated Aplastic Anemia. Acta Haematologica. 2026:1-14. doi:10.1159/000551296
BibTeX
@article{Li2026,
author = {Li, Xinxin and Wu, Liangliang and Li, Yumiao and Mo, Wenjian and Chen, Xiaowei and Zhou, Ming and Zhou, Ruiqing and Xu, Shilin and Pan, Shiyi and Wang, Caixia and Wang, Shunqing and Zhang, Yuping},
title = {Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pregnancy-Associated Aplastic Anemia},
journal = {Acta Haematologica},
year = {2026},
pages = {1--14},
doi = {10.1159/000551296}
}
EUVIMED